NLRP3 and Hyperglycemia: Meanwhile, therapeutic effects of IL-22 gene therapy were apparent despite initiation of treatment 17 weeks after persistent hyperglycemia and nephropathy onset, reflecting at least partial disease reversal by targeting renal NLRP3 inflammasome.